Head to Head Analysis: Acurx Pharmaceuticals (NASDAQ:ACXP) versus MoonLake Immunotherapeutics (NASDAQ:MLTX)

Acurx Pharmaceuticals (NASDAQ:ACXP) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Acurx Pharmaceuticals and MoonLake Immunotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97 million	($4.05)	-0.41
MoonLake Immunotherapeutics	N/A	N/A	-$227.32 million	($3.87)	-4.63

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Acurx Pharmaceuticals and MoonLake Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1	0	1	0	2.00
MoonLake Immunotherapeutics	3	4	9	0	2.38

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,745.24%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 33.22%. Given Acurx Pharmaceuticals’ higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Profitability

This table compares Acurx Pharmaceuticals and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Volatility & Risk

Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Summary

MoonLake Immunotherapeutics beats Acurx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.